Join the club for FREE to access the whole archive and other member benefits.

Company introduces 'gene writing', to surpass CRISPR's limitations

New class of gene editors set to remove hurdles of traditional gene therapy


Key points from article :

Tessera Therapeutics developing a new class of gene editors that can plug in long stretches of DNA.

This is something CRISPR cannot do, calling it "gene writing" not editing.

Gene writing is able to make either perfect deletions or simple base pair changes.

Their experts are in search of mobile genetic elements (MGEs) suited to make these DNA changes.

Identified ~6,000 retrotransposons (Tessera calls RNA writers), 2,000 transposons (DNA writers).

35 scientists have been conducting experiments in human cells to test each one.

In mouse models, team has consistently been able to use them.

This is to insert copies of large green fluorescent protein gene into animals' genomes.

What's different about Tessera is that they only need to inject a bit of RNA to make changes.

Adding chunks if reparative genetic code to treat certain conditions will be easier.

Genetic medicine to be one of the most extraordinary new categories of medicine.

Mentioned in this article:

Click on resource name for more details.

Cornell University

Private Ivy League research university in New York.

CRISPR Therapeutics

Company developing transformative gene-based medicines for serious human diseases

Eugene Koonin

Senior Investigator at the National Center for Biotechnology Information, NIH

Geoffrey von Maltzahn

CEO, Tessera Therapeutics

Joseph (Joe) Peters

Professor, Microbiology

Kira Makarova

Scientist at the National Center for Biotechnology Information

National Institutes of Health (NIH)

Medical research agency that supports scientific studies

Tessera Therapeutics

Genetic medicine company

Topics mentioned on this page:
Gene Therapy